BIBA Research's TAVI report to be released

BIBA Research, the UK-based market research specialists for the medical technology industry, announced today that the latest findings from their Transcatheter Heart Valve (TAVI) report will be released on 26 April. The report covers the data period January-March 2010 and is part of BIBA Research's long-established European Cardiovascular Monitor.

This monitor on transcatheter heart valve was launched in coincidence with the TCT Conference in S. Francisco last year and represents the largest third-party investigation on market trends and penetration of transcatheter heart valve replacement and repair technologies in W. Europe.

This monitor tracks quarterly device consumption from a panel of over 300 hospitals in 15 countries and will answer critical questions such as:

- How fast is the transcatheter heart valve market growing? - What is the transfemoral /transapical procedural split? - Who is winning the market share battle between Medtronic CoreValve and Edwards Sapien? - What is the status of emerging technology platforms?

Transcatheter (also known as percutaneous) heart valve implantation has one of the strongest growth potentials in medical technology today. The first implantation of an aortic valve in humans was performed by French cardiologist Alain Cribier in 2002. Since then, transcatheter heart valve procedures have recorded constant double-digit growth on year, as an increasing number of centres have introduced this programme, offering a new therapeutic option to candidates not suitable for conventional surgery.

"We are very pleased to enhance our leadership in the market analysis field of Transcatheter heart valve technology," said Stephen Greenhalgh, BIBA's Managing Director. "This monitor reaches a very large number of institutions and provides valuable information to financial analysts and investors. The aim of this service is to provide clients with the key-information to make strategic decisions."

BIBA also announced that a discussion on transcatheter aortic valve replacement will be held on Monday 12 April within the Complex Case Review session at the forthcoming edition of Charing Cross International Symposium. The Charing Cross International Symposium, which will be held from 10 to 13 April in London, is Europe's longest running and leading vascular congress. This year's edition of Charing Cross is expected to attract over 2,500 specialists from 71 countries.